{"id":"W3005292744","doi":"10.1016/s1470-2045(19)30801-0","title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"Merck Sharp and Dohme; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Carboplatin; Internal medicine; Placebo; Response Evaluation Criteria in Solid Tumors; Oncology; Cancer; Surgery; Progressive disease; Chemotherapy; Cisplatin; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009146474,0.0006731031,0.003037033,0.0002180132,0.0002007834,0.00006977404,0.0002801542,0.0002383213,0.0002485855],"category_scores_gemma":[0.0003629086,0.0003788592,0.0003727585,0.0005916203,0.0001603484,0.0001447824,0.0001103596,0.0006394096,0.000005925468],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006185758,"about_ca_system_score_gemma":0.001172344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001268614,"about_ca_topic_score_gemma":0.001790372,"domain_scores_codex":[0.9957497,0.0005034042,0.001441839,0.0007830829,0.0005537744,0.0009681894],"domain_scores_gemma":[0.9964872,0.001503211,0.0009949688,0.0005420194,0.0001540516,0.0003185548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9518723,0.001286545,0.03062209,0.0002725505,0.002690653,0.000528646,0.006779513,0.0002058239,0.0002347356,5.33099e-7,0.0004716793,0.00503493],"study_design_scores_gemma":[0.9795827,0.007788531,0.002004673,0.000179569,0.0034069,0.00001999954,0.0008284522,0.004893707,0.0002526384,8.017948e-7,0.0005740605,0.0004679349],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9753358,0.0008747492,0.000136365,0.001627514,0.0005272906,0.02069324,0.00005214998,0.00009363948,0.0006592541],"genre_scores_gemma":[0.9939695,0.0002043958,0.0004773338,0.00210383,0.0002365314,0.002493558,0.0001080565,0.00009262889,0.0003141558],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02861742,"threshold_uncertainty_score":0.9998663,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04083119283367594,"score_gpt":0.3379551712156635,"score_spread":0.2971239783819876,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}